Global Anatomic Pathology Market Size & Trends Report Segmented by Products & Services (Instruments, Consumables, Services), Application (Disease Diagnosis, Drug Discovery and Development), End-user (Hospitals, Research & Diagnostic Laboratories) & Regional Forecast to 2030

The global anatomic pathology market is expected to grow at a CAGR of ~8% during the forecast period. The high incidence of cancer and other chronic disorders, growing focus on personalized medicine, increasing emphasis on early diagnosis & prevention, and expanding applications in oncology, gastroenterology, and gynecology are some of the key driving factors supporting the market growth. However, the lack of skilled professionals and high costs of advanced pathology instruments and maintenance may hinder the market growth. To learn more about the research report, download a sample report.

Overview

Anatomic pathology is a specialized branch of pathology that involves the study of the structural and morphological characteristics of tissues and organs to understand the nature and cause of diseases. It primarily focuses on the examination of tissue specimens, which may be obtained through biopsies, surgical resections, or autopsies. The goal of anatomic pathology is to identify abnormalities in cells and tissues, helping physicians make accurate diagnoses, determine the severity of diseases, and guide appropriate treatment plans-especially in fields like oncology, gastroenterology, and gynecology.

To learn more about this report, download the PDF brochure

Anatomic pathology market is evolving with the adoption of personalized medicine and AI

The increasing demand for personalized medicine is a major catalyst contributing to the expansion of the anatomic pathology market. Personalized medicines are tailored based on an individual-s genetic profile to ensure precise diagnosis, and treatment. For instance, personalized anticancer treatments offer targeted mechanisms of action, resulting in fewer and less severe side effects compared to conventional therapies. These therapies, while most established in "https://meditechinsights.com/oncology-information-system-market/">oncology, are increasingly being applied in other areas such as cardiovascular disease through pharmacogenomic testing for drug response and autoimmune disorders, where biomarker profiling supports more targeted use of biologics. This growing adoption of personalized therapeutic approaches is expected to drive substantial growth within the anatomic pathology market. Further the integration of AI into pathology is increasingly supporting genomic profiling and biomarker discovery making personalized medicine more accessible, scalable, and responsive to complex disease profiles.

To learn more about this report, download the PDF brochure

Rising demand for companion diagnostics accelerates the anatomic pathology market growth

The rising demand for companion diagnostics (CDx) is one of the primary drivers accelerating the growth of anatomic pathology market. Anatomic pathology serves as the foundation for companion diagnostics by providing detailed insights into tumor morphology, cellular architecture, and molecular alterations. Advanced techniques such as immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS) are used to examine tissue samples, thereby enabling the detection of genetic mutations and protein expressions, which remains essential in determining a patient-s eligibility for targeted therapies. By leveraging these insights, healthcare professionals can tailor treatments to an individual-s unique biomarker profile, improve clinical outcomes, minimize adverse effects, and avoid ineffective therapies thereby lowering both clinical and economic burden.

Recent developments in the anatomic pathology market

The anatomic pathology landscape is driven by innovation across various sectors including companion diagnostics, liquid biopsy, and digital pathology platforms. Leading healthcare providers and diagnostic laboratories are expanding their portfolios to enhance diagnostic precision, accelerate turnaround times, and enable personalized treatment strategies. For instance,

• In May 2025, NeoGenomic Inc. annh of its c-MET CDx for NSCLC, a companion diagnostic assay that detects c-Met protein overexpression in advanced non-small cell lung cancer patients with a 48-hour turnaround time
• In April 2025, Labcorp introduced two liquid biopsy solutions: Labcorp Plasma Detect, a whole-genome sequencing test for detecting molecular residual disease (MRD) and recurrence risk in stage III colon cancer, and PGDx elio plasma focus Dx, the first FDA-authorized pan-solid tumor liquid biopsy kit for guiding targeted therapy selection from blood samples
• In July 2024, Danaher Corporation announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of companion diagnostics (cdx) and complementary diagnostics (codx)

Competitive Landscape Analysis

The global anatomic pathology market comprises of several well-established and emerging players, including F. Hoffmann-La Roche Ltd.; Danaher Corporation; "https://www.agilent.com/">Agilent Technologies; Merck KGaA; Cardinal Health, Inc.; -PHC Holdings Corp.; PerkinElmer, Inc; Becton, Dickinson and Company; Laboratory Corporation of America (LabCorp); NeoGenomics Laboratories, Inc among others. Key strategies adopted by these players include the development of advanced diagnostic technologies (such as multiplexed biomarker assays and precision tissue staining platforms), mergers and acquisitions, and investment in R&D to enhance pathology workflows, support personalized medicine initiative and meet growing global demand.